prikaz prve stranice dokumenta Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars
Rad nije dostupan
Znanstveni rad - Izvorni znanstveni rad
Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars
Expert opinion on biological therapy, 17 (2017), 8; 915-926. https://doi.org/10.1080/14712598.2017.1341486
Inotai, András; Prins, Christiaan; Csanádi, Marcell; Vitezić, Dinko; Codreanu, Catalin; Kaló, Zoltán

Citirajte ovaj rad

Inotai, A., Prins, C., Csanádi, M., Vitezić, D., Codreanu, C. i Kaló, Z. (2017). Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. Expert opinion on biological therapy, 17. (8), 915-926. doi: 10.1080/14712598.2017.1341486

Inotai, András, et al. "Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars." Expert opinion on biological therapy, vol. 17, br. 8, 2017, str. 915-926. https://doi.org/10.1080/14712598.2017.1341486

Inotai, András, Christiaan Prins, Marcell Csanádi, Dinko Vitezić, Catalin Codreanu i Zoltán Kaló. "Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars." Expert opinion on biological therapy 17, br. 8 (2017): 915-926. https://doi.org/10.1080/14712598.2017.1341486

Inotai, A., et al. (2017) 'Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars', Expert opinion on biological therapy, 17(8), str. 915-926. doi: 10.1080/14712598.2017.1341486

Inotai A, Prins C, Csanádi M, Vitezić D, Codreanu C, Kaló Z. Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. Expert opinion on biological therapy [Internet]. 2017. [pristupljeno 05.12.2024.];17(8):915-926. doi: 10.1080/14712598.2017.1341486

A. Inotai, C. Prins, M. Csanádi, D. Vitezić, C. Codreanu i Z. Kaló, "Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars", Expert opinion on biological therapy, vol. 17, br. 8, str. 915-926, 2017. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:992083. [Citirano: 05.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:992083
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars
AutorAndrás Inotai
AutorChristiaan Prins
AutorMarcell Csanádi
AutorDinko Vitezić
AutorCatalin Codreanu
AutorZoltán Kaló
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za farmakologiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Farmakologija
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
Introduction: While prescribing biosimilars to patients naive to a biologic treatment is a well- accepted practice, switching clinically stable patients from an originator to a biosimilar is an issue for clinicians. Well designed clinical trials and real-world data which study the consequences of switching from an originator biologic treatment to its biosimilar alternative are limited, especially for monoclonal antibodies. Areas covered: A systematic literature review was conducted on PubMed to identify evidence of the consequences of switching from original biologics to biosimilars. References of included papers were also scrutinized. After a title-, abstract- and full text screening, out of the 153 original hits and 77 additional ones from screening the references, 58 papers (12 empirical papers, 5 systematic reviews and 41 non-empirical papers) were included. Expert opinion: Preventing patients on biologic medicines from switching to biosimilars due to anticipated risks seems to be disproportional compared to the expected cost savings and/or improved patient access. Indeed, it is the opinion of the authors that the concern of switching to biosimilars is overhyped.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaExpert opinion on biological therapy
Brojčani podacivol. 17, br. 8, str. 915-926
p-ISSN1471-2598
DOIhttps://doi.org/10.1080/14712598.2017.1341486
URN:NBNurn:nbn:hr:184:992083
Datum objave publikacije2017
ProjektŠifra: 062-0620063-0060
Naziv (hrvatski): Uporaba kardiovaskularnih lijekova i značaj farmakoekonomskih procjena
Naziv (engleski): Cardiovascular drugs usage and the importance of pharmacoeconomic evaluations
Voditelj: Dinko Vitezić
Pravna nadležnost: Hrvatska
Financijer: MZOS
Linija financiranja: ZP
URL dokumentahttp://bib.irb.hr/881000
Vrsta resursaTekst
Prava pristupaZatvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2022-02-23 17:24:04